Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Mirati Ther (MRTX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Mirati Ther's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
58.80 -4.78    -7.52%
24/05 - Closed. Currency in USD ( Disclaimer )
After Hours
57.74
-1.06
-1.80%
17:40:30 - Real-time Data
Type:  Equity
Market:  United States
ISIN:  US60468T1051 
CUSIP:  60468T105
  • Volume: 505,792
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 58.30 - 63.00
Mirati Ther 58.80 -4.78 -7.52%
IndustryBiotechnology
SectorHealthcare
Employees

-

Equity Type

ORD

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Contact Information

Phone 858 332 3410
Fax -

Top Executives

Name Age Since Title
Henry J. Fuchs 63 2012 Independent Director
Pasi Antero Janne - 2019 Member of Scientific Advisory Board
George Daniel Demetri 64 - Member of Scientific Advisory Board
Stephen B. Baylin - - Member of Scientific Advisory Board
Aaron I. Davis 43 2018 Independent Director
Channing J. Der - 2019 Member of Scientific Advisory Board
Julie Michele Cherrington 63 2019 Independent Director
Maria E. Martinez-Davis 51 2018 Independent Director
Craig A. Johnson 59 2013 Independent Director
Shalini Sharp 46 2021 Independent Director
Bruce Leonard Andrews Carter 78 2016 Independent Director
Lillian L. Siu - - Member of Scientific Advisory Board
Faheem Hasnain 64 2019 Chairman & Lead Independent Director
Charles M. Baum 64 2012 Founder, President, Head of Research & Development and Director
David D. Meek 59 2021 CEO & Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MRTX Comments

Write your thoughts about Mirati Ther
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email